Clarity in action

We are determined to bring the full power of data to the collective fight against cancer.

Our Approach

Through our research and partnerships, we are helping to shape the real-world evidence industry and advance the field of oncology.

Our collaborations are leading industry to advance the treatment landscape, reimagine the drug development life cycle, and accelerate value-based care models.

Our Research and Publications

Discover more about how our work with the FDA, industry and academia helps to ensure that everyone touched by cancer is given a clear path to the right care.

3 Key Attributes of Every Successful Value-Focused Oncology Practice

Oncology practices, especially providers participating in value-based reimbursement programs from the Centers for Medicare and Medicaid Services (CMS) like the Oncology Care Model (OCM), are under pressure to measure and improve performance.

Prospective Assessment of the Value of Genomic Profiling in Metastatic Lung Cancer

This prospective observational study is designed to reveal genomic profiling patterns and the influence of testing on clinical and economic outcomes among patients with advanced lung cancer in real world settings.

Digital characterization of breast cancer phenotypes to identify variances in care and costs at scale

This study applies the novel Cota Nodal Address (CNA) digital system to a consecutive cohort of patients with breast cancer to identify population frequencies of subtypes and variances in treatment patterns and total costs of care for one year following diagnosis.

Are patients with advanced cancer concerned about financial toxicity?

Cancer patients are more than twice as likely to enter bankruptcy as the general US population. It is unknown how often patients with metastatic cancer are concerned about the financial toxicities of treatment.

Development of a Patient Reported Outcome Instrument to Facilitate Timing of End-of-Life Discussions in Patients with Advanced Cancers

Honoring the wishes of terminally ill cancer patients is a prime responsibility of oncologists, however end of life (EOL) discussions are frequently either never performed or delayed past the point of usefulness.

A new digital classification schema to detect treatment variances and enable value based payment reforms

Value based payment reforms which improve the outcome to cost ration (paying for outcomes not for services) require detailed information on both elements.

COTA in the News

COTA Signs Research Agreement with the FDA

COTA signs a two-year Research Collaboration Agreement (RCA) with the FDA to study variation in cancer treatment patterns using real-world data. This RCA will provide the FDA with information on the evolving breast cancer treatment landscape, including insight on treatment variation.


COTA Wins eyeforpharma Health Tech Challenge

Every pharma company wants to work with startups – for good reason. Startups work with agility to find solutions that often address patients’ unmet needs. As our industry commits to providing more patient value, eyeforpharma is committed to showcasing the brightest and best startups.


Our collective responsibility
to apply real-world evidence

FDA and COTA recently finalized a research collaboration agreement. Research efforts are underway across tumor types to assess the utility of RWE in drug development for high unmet need populations and in accelerating clinical trials.

Friends of Cancer Research and COTA partnered in a pilot study of immune checkpoint inhibitors approved for non-small cell lung cancer to define a standard data framework and to assess correlation between real-world endpoints and overall survival.

Let’s work together to transform cancer care.